Sanofi (NASDAQ:SNY) Stake Raised by Park Avenue Securities LLC

Park Avenue Securities LLC increased its holdings in Sanofi (NASDAQ:SNY) by 14.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,982 shares of the company’s stock after buying an additional 8,615 shares during the quarter. Park Avenue Securities LLC’s holdings in Sanofi were worth $3,327,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC increased its stake in shares of Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares during the period. Jennison Associates LLC raised its holdings in Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after purchasing an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 2.7 %

NASDAQ SNY opened at $50.70 on Friday. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a market capitalization of $128.66 billion, a P/E ratio of 25.86, a PEG ratio of 1.17 and a beta of 0.57. The company’s 50 day simple moving average is $48.49 and its 200 day simple moving average is $52.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.55 EPS. Equities research analysts expect that Sanofi will post 3.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.